Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay
Open Access
- 1 February 2013
- journal article
- Published by Elsevier BV in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 78-79, 39-44
- https://doi.org/10.1016/j.jpba.2013.01.031
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Management of Inflammatory Bowel Disease with Infliximab and Other Anti-Tumor Necrosis Factor Alpha TherapiesBioDrugs, 2010
- Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2008
- Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology productsJournal of Pharmaceutical and Biomedical Analysis, 2008
- Immunogenicity of anti-tumor necrosis factor antibodies—toward improved methods of anti-antibody measurementCurrent Opinion in Immunology, 2008
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive reviewPharmacology & Therapeutics, 2007
- Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trialGut, 2007
- Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2007
- Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximabArthritis & Rheumatism, 2006
- Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I TrialGastroenterology, 2006
- Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s diseaseGastroenterology, 2003